Italia markets close in 3 hours 58 minutes

FTSE MIB
34.765,00
+272,59(+0,79%)
Dow Jones
38.686,32
+574,82(+1,51%)
Nasdaq
16.735,02
-2,08(-0,01%)
Nikkei 225
38.923,03
+435,13(+1,13%)
Petrolio
77,08
+0,09(+0,12%)
Bitcoin EUR
63.810,37
+1.488,80(+2,39%)

NVCR Jan 2025 155.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,6800

0,0000

(0,00%)

In data: 02:30PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in